Insights

On August 1, 2024, the Department of Justice’s Criminal Division launched a three-year Corporate Whistleblower Awards Pilot Program. In this article, we provide an overview of the Pilot Program and lay out the recent changes to the guidance.

Since 2018, there has been an exponential growth of over US$60 billion of licensing deals involving Antibody Drug Conjugates (ADCs), with 2023 having at least 18 deals. ADCs worldwide are projected to reach US$20-30 billion per year in the near future.

Since 2018, licensing deals totaling over $60 billion have been signed regarding Antibody Drug Conjugates (ADCs), with 2023 alone having at least 18 deals.

The Securities & Exchange Commission, the Department of Health & Human Services, and other agencies have long had established bounty programs that reward successful tipsters.

The first step to making a product available to the clinical population is often obtaining patent protection, resulting in litigation around ADCs.

On May 30, 23 Senators signed a letter to the Attorney General, calling on the U.S. Department of Justice’s Antitrust Division to “use every tool” to investigate the oil industry for potential violations of the Sherman Antitrust Act, including price fixing.

Foley & Lardner’s 2024 Health Care & Life Sciences Top Trends publication unpacks fast-moving developments to help your business.

The FDA revised its emergency use authorization (EUA) for the COVID-19 antiviral treatment Paxlovid to allow prescribing by pharmacists.